252 related articles for article (PubMed ID: 23689766)
1. Trends in reporting methadone-associated cardiac arrhythmia, 1997-2011: an analysis of registry data.
Kao D; Bucher Bartelson B; Khatri V; Dart R; Mehler PS; Katz D; Krantz MJ
Ann Intern Med; 2013 May; 158(10):735-40. PubMed ID: 23689766
[TBL] [Abstract][Full Text] [Related]
2. Arrhythmia associated with buprenorphine and methadone reported to the Food and Drug Administration.
Kao DP; Haigney MC; Mehler PS; Krantz MJ
Addiction; 2015 Sep; 110(9):1468-75. PubMed ID: 26075588
[TBL] [Abstract][Full Text] [Related]
3. QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system.
Pearson EC; Woosley RL
Pharmacoepidemiol Drug Saf; 2005 Nov; 14(11):747-53. PubMed ID: 15918160
[TBL] [Abstract][Full Text] [Related]
4. Disproportionality analysis of buprenorphine transdermal system and cardiac arrhythmia using FDA and WHO postmarketing reporting system data.
Sessler NE; Walker E; Chickballapur H; Kacholakalayil J; Coplan PM
Postgrad Med; 2017 Jan; 129(1):62-68. PubMed ID: 27977317
[TBL] [Abstract][Full Text] [Related]
5. Methadone maintenance, QTc and torsade de pointes: who needs an electrocardiogram and what is the prevalence of QTc prolongation?
Mayet S; Gossop M; Lintzeris N; Markides V; Strang J
Drug Alcohol Rev; 2011 Jul; 30(4):388-96. PubMed ID: 21355918
[TBL] [Abstract][Full Text] [Related]
6. Drug-induced torsades de pointes in an underserved urban population. Methadone: is there therapeutic equipoise?
Romero J; Baldinger SH; Goodman-Meza D; Engstrom K; Valencia CR; Golive A; Medrano F; Rangasamy S; Makkiya M; Fisher JD; Gross J; Krumerman A; Kim S; Garcia MJ; Di Biase L; Ferrick KJ
J Interv Card Electrophysiol; 2016 Jan; 45(1):37-45. PubMed ID: 26589717
[TBL] [Abstract][Full Text] [Related]
7. Proarrhythmic potential of dronedarone: emerging evidence from spontaneous adverse event reporting.
Kao DP; Hiatt WR; Krantz MJ
Pharmacotherapy; 2012 Aug; 32(8):767-71. PubMed ID: 22744806
[TBL] [Abstract][Full Text] [Related]
8. Summary of Torsades de Pointes (TdP) Reports Associated with Intravenous Drug Formulations Containing the Preservative Chlorobutanol.
Woosley RD; Romero K; Heise CW; Gallo T; Tate J; Woosley RL
Drug Saf; 2019 Jul; 42(7):907-913. PubMed ID: 30888625
[TBL] [Abstract][Full Text] [Related]
9. Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes.
Krantz MJ; Kutinsky IB; Robertson AD; Mehler PS
Pharmacotherapy; 2003 Jun; 23(6):802-5. PubMed ID: 12820821
[TBL] [Abstract][Full Text] [Related]
10. Association of H1-antihistamines with torsade de pointes: a pharmacovigilance study of the food and drug administration adverse event reporting system.
Ali Z; Ismail M; Khan F; Sajid H
Expert Opin Drug Saf; 2021 Jan; 20(1):101-107. PubMed ID: 33141610
[No Abstract] [Full Text] [Related]
11. Effects of buprenorphine on cardiac repolarization in a patient with methadone-related torsade de pointes.
Krantz MJ; Garcia JA; Mehler PS
Pharmacotherapy; 2005 Apr; 25(4):611-4. PubMed ID: 15977920
[TBL] [Abstract][Full Text] [Related]
12. QT prolongation and Torsades de Pointes in patients infected with human immunodeficiency virus and treated with methadone.
Gil M; Sala M; Anguera I; Chapinal O; Cervantes M; Guma JR; Segura F
Am J Cardiol; 2003 Oct; 92(8):995-7. PubMed ID: 14556883
[TBL] [Abstract][Full Text] [Related]
13. Torsades de pointes and QT prolongation Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System.
Teng C; Walter EA; Gaspar DKS; Obodozie-Ofoegbu OO; Frei CR
Int J Med Sci; 2019; 16(7):1018-1022. PubMed ID: 31341415
[No Abstract] [Full Text] [Related]
14. QT interval prolongation: prevalence, risk factors and pharmacovigilance data among methadone-treated patients in France.
Perrin-Terrin A; Pathak A; Lapeyre-Mestre M
Fundam Clin Pharmacol; 2011 Aug; 25(4):503-10. PubMed ID: 20825488
[TBL] [Abstract][Full Text] [Related]
15. Protease inhibitor-associated QT interval prolongation.
Hunt K; Hughes CA; Hills-Nieminen C
Ann Pharmacother; 2011 Dec; 45(12):1544-50. PubMed ID: 22128044
[TBL] [Abstract][Full Text] [Related]
16. QTc Prolongation in Poison Center Exposures to CredibleMeds List of Substances with "Known Risk of Torsades de Pointes".
Ryan K; Benz P; Zosel A; Farkas A; Theobald J
Cardiovasc Toxicol; 2022 Sep; 22(9):866-877. PubMed ID: 35930218
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneous impact of methadone on the QTc interval: what are the practical implications?
Krantz MJ
J Addict Dis; 2008; 27(4):5-9. PubMed ID: 19042586
[TBL] [Abstract][Full Text] [Related]
18. Torsade de pointes associated with very-high-dose methadone.
Krantz MJ; Lewkowiez L; Hays H; Woodroffe MA; Robertson AD; Mehler PS
Ann Intern Med; 2002 Sep; 137(6):501-4. PubMed ID: 12230351
[TBL] [Abstract][Full Text] [Related]
19. Citalopram, QTc interval prolongation, and torsade de pointes. How should we apply the recent FDA ruling?
Vieweg WV; Hasnain M; Howland RH; Hettema JM; Kogut C; Wood MA; Pandurangi AK
Am J Med; 2012 Sep; 125(9):859-68. PubMed ID: 22748401
[TBL] [Abstract][Full Text] [Related]
20. Methadone induced torsade de pointes in a patient receiving antiretroviral therapy.
Falconer M; Molloy D; Ingerhaug J; Barry M
Ir Med J; 2007; 100(10):631-2. PubMed ID: 18277734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]